Altimmune, Inc. Common Stock

Day range

$2.06 – $2.15

Open

$2.13

Prev close

$2.12

Volume

1.87M

Market cap

$412.38M

Shares out

194.52M

P/E

—

P/S

13302.50

P/B

0.87

P/FCF

—

ROE

-19.4%

ROA

-17.5%

Debt/Equity

0.07

Div yield

0.00%

As of Oct 23, 2026

• Executive officer appointmentSep 29, 2026

  On September 24, 2026, the Board of Directors (the "Board") of Altimmune, Inc. (the "Company") appointed Richard Menziuso as the Company's Vice President, Global Controller and Principal Accounting Officer effective as of September 29, 2026.

• Clinical trial resultsJul 28, 2026

  On July 28, 2026, Altimmune, Inc. (the "Company") issued a press release announcing the positive topline results from the RECLAIM Phase 2 trial evaluating pemvidutide 2.4 mg dose, an investigational balanced glucagon/GLP-1 dual receptor agonist, in patients with moderate to severe alcohol use disorder (AUD). The trial met its primary endpoint with a highly statistically significant reduction in heavy drinking days per week (HDD) versus placebo, with positive results across important secondary endpoints, including a two-level reduction in the World Health Organization Risk Drinking Level and zero HDDs, both of which are U.S. Food and Drug Administration (FDA) registrational endpoints, as well as a reduction in phosphatidyl ethanol levels. A generally favorable safety and tolerability profile was observed in the trial.

• Lease agreementJun 16, 2026

  The Company has entered into an office lease agreement for the New Jersey headquarters where the Company will make rent payments of approximately $300,000 annually for the 5-year lease term.

• Public offeringApr 24, 2026

  On April 22, 2026, Altimmune, Inc. entered into an underwriting agreement pursuant to which the Company agreed to issue and sell (i) 64,250,000 shares of the Company's common stock and accompanying common stock warrants at a public offering price of $3.00 per share and (ii) pre-funded warrants to purchase up to 10,750,000 shares of Common Stock at a public offering price of $2.999 per Pre-Funded Warrant. The Offering closed on April 24, 2026.

• Charter amendmentApr 16, 2026

  On April 16, 2026, Altimmune, Inc. (the "Company") amended its Amended and Restated Certificate of Incorporation (the "Certificate of Incorporation") by filing a Certificate of Amendment with the Secretary of State of Delaware. The Certificate of Amendment reflected an amendment to increase the number of authorized shares of common stock from 200,000,000 to 400,000,000.

Days to cover

10.5

Short interest

46.08M

Avg volume

4.37M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Metabolic Dysfunction-Associated Steatohepatitis Clinical Trial and Competitive Landscape Expands as 180+ Companies Target New Treatment Options | DelveInsight
  positiveGlobeNewswire Inc.· Oct 20, 2026
• Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?
  neutralZacks Investment Research· Oct 7, 2026
• Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?
  positiveZacks Investment Research· Sep 11, 2026
• Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight
  positiveGlobeNewswire Inc.· Jun 8, 2026
• Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026
  positiveGlobeNewswire Inc.· May 28, 2026